Narmac

"long-term" could also infer that the FDA has requested a higher number than the ~ 600 remaining trial participants for  US testing. I still have not seen a corporate response to FDA's requested changes in trial design which could possibly push this out another year. Perhaps the RVX proposed trial redesign is  being evaluated  or has been rejected by the FDA further delaying the trial readout past 2H-2018 and NPV of future revenues.

Chicagoest